Amr Hanbali, Ahmed Kotb, Riad El Fakih, Feras Alfraih, Nahla Shihata, Walid Rasheed, Syed Osman Ahmed, Marwan Shaheen, Saud Alhayli, Ali Alahmari, Ahmad Alotaibi, Alfadel Alshaibani, Abdulwahab Albabtain, Mansour Alfayez, Maha Hassan, Fahad Alsharif, Naeem Chaudhri, Fahad Almohareb, Hazzaa Alzahrani, Mahmoud Aljurf
{"title":"Improved survival of adolescents and young adults patients with T-cell acute lymphoblastic leukemia.","authors":"Amr Hanbali, Ahmed Kotb, Riad El Fakih, Feras Alfraih, Nahla Shihata, Walid Rasheed, Syed Osman Ahmed, Marwan Shaheen, Saud Alhayli, Ali Alahmari, Ahmad Alotaibi, Alfadel Alshaibani, Abdulwahab Albabtain, Mansour Alfayez, Maha Hassan, Fahad Alsharif, Naeem Chaudhri, Fahad Almohareb, Hazzaa Alzahrani, Mahmoud Aljurf","doi":"10.2217/ijh-2022-0005","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>The outcome of T-cell acute lymphoblastic leukemia (T-ALL) has improved with the use of pediatric-inspired protocols in the adolescents and young adults (AYA) population. There is limited literature regarding the outcome of T-ALL/lymphoblastic lymphoma (LBL) AYA patients treated with pediatric protocols.</p><p><strong>Methods: </strong>A total of 35 T-ALL/LBL-AYA patients ages between 14 and 55 years were treated with AYA-15 protocol.</p><p><strong>Results: </strong>At a median follow-up of 5 years the overall survival, disease-free survival and event-free survival are 71%, 62% and 49.6% respectively. Toxicities were within the expected range.</p><p><strong>Conclusion: </strong>Our single-center experience real-world data in treating T-ALL/LBL-AYA patients with pediatric-inspired protocol demonstrates encouraging results of high survival rate and excellent tolerability for patients aged 18-55 years.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"12 1","pages":"IJH42"},"PeriodicalIF":0.0000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/16/69/ijh-12-42.PMC9979159.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Hematologic Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/ijh-2022-0005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Aim: The outcome of T-cell acute lymphoblastic leukemia (T-ALL) has improved with the use of pediatric-inspired protocols in the adolescents and young adults (AYA) population. There is limited literature regarding the outcome of T-ALL/lymphoblastic lymphoma (LBL) AYA patients treated with pediatric protocols.
Methods: A total of 35 T-ALL/LBL-AYA patients ages between 14 and 55 years were treated with AYA-15 protocol.
Results: At a median follow-up of 5 years the overall survival, disease-free survival and event-free survival are 71%, 62% and 49.6% respectively. Toxicities were within the expected range.
Conclusion: Our single-center experience real-world data in treating T-ALL/LBL-AYA patients with pediatric-inspired protocol demonstrates encouraging results of high survival rate and excellent tolerability for patients aged 18-55 years.
期刊介绍：
International Journal of Hematologic Oncology welcomes unsolicited article proposals. Email us today to discuss the suitability of your research and our options for authors, including Accelerated Publication. Find out more about publishing open access with us here.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
